QURE
uniQure N.V.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
uniQure N.V.
26.50
uniQure has 7 disclosed suppliers and 3 disclosed customers in SEC filings.
SentenceDuring the year ended December 31, 2023, we incurred expenses of $10.0 million related to the upfront consideration paid to Apic Bio for the global licensing rights to AMT-162.
QURE 10-Kaccession 0001104659-26-021898
SentenceOur miQURE gene silencing platform, based on exclusively licensed technology from Cold Spring Harbor Laboratory ("CSHL"), is designed to degrade mutated genes without producing a "passenger strand" thereby mitigating potential off-target toxicity and induce silencing of the mutated gene in the entire target organ through secondary exosome-mediated delivery.
QURE 10-Kaccession 0001104659-26-021898
SentenceIn connection with the July 2024 closing of the Lexington Transaction, we and Genezen entered into certain additional agreements, including a commercial supply agreement pursuant to which Genezen will manufacture and supply our requirements of HEMGENIX pursuant to our manufacturing and supply obligations to CSL Behring, and development and other manufacturing services agreement pursuant to which Genezen will manufacture, supply and provide certain development services to support the requirements of our investigational gene therapy programs and for other discretionary services related to the manufacture of HEMGENIX, along with other customary agreements.
QURE 10-Kaccession 0001104659-26-021898
SentenceIn addition, in July 2024, as part of the closing of the asset purchase agreement among our affiliates, uniQure Inc. and uniQure biopharma B.V. ("uniQure biopharma"), and Genezen Holdings Inc. and its subsidiary Genezen MA, Inc. (together "Genezen") to sell certain assets and assume certain liabilities related to our former manufacturing facility and operations in Lexington, Massachusetts (the "Lexington Transaction"), we transferred the manufacturing and supply activities to Genezen such that Genezen manufactures and supplies CSL Behring's commercial demand for HEMGENIX on our behalf.
QURE 10-Kaccession 0001104659-26-021898
SentenceIn 2008, we entered into a license agreement with St. Jude Children's Research Hospital ("St. Jude"), which we amended in 2012.
QURE 10-Kaccession 0001104659-26-021898
SentenceWe and CSL Behring also entered into a development and commercial supply agreement, pursuant to which, among other things, we agreed to supply the product to CSL Behring.
QURE 10-Kaccession 0001104659-26-021898
SentenceIn the year ended December 31, 2025, we recognized $6.0 million in income related to a one-time sale of critical reagents to Genezen, compared to nil in the same periods in 2024 and 2023.
QURE 10-Kaccession 0001104659-26-021898
SentenceIn May 2023, uniQure biopharma entered into an agreement (the "Royalty Financing Agreement") with HemB SPV, L.P. to sell certain current and future royalties due to uniQure biopharma from CSL Behring under the CSL Behring Agreement by and between uniQure biopharma and CSL Behring from the net sales of HEMGENIX.
QURE 10-Kaccession 0001104659-26-021898
Linked news
Expected move
Inputsstraddle ±21.7%
spot 24.83exp Nov 20ATM strike 25ATM straddle 6.33IV 132%